- Details
- Neeraj Agarwal leads a discussion with Martin Schoen and Bruce Montgomery about a study examining treatment patterns and outcomes for veterans with metastatic hormone-sensitive prostate cancer. The research reveals that VA patients demonstrate longer survival rates compared to the general U.S. population, particularly among younger patients, with combination therapy now being utilized in approxima...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Oliver Sartor discusses the management of synchronous, low-volume, metastatic hormone-sensitive prostate cancer. The presentation analyzes data from major trials like PEACE-1 and ARASENS while addressing the benefits of prostate radiation and acknowledging the complexity of real-world treatment decisions. Biographies: Oliver Sartor...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Nicholas James presents an analysis of triplet therapy in prostate cancer treatment, examining evidence from the PEACE-1, ARASENS, and ENZAMET trials. Through network meta-analysis, he explores the comparative effectiveness of different treatment combinations and proposes a framework based on disease characteristics. Biographies: N...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Sandy Srinivas examines the role of radiation therapy to the primary tumor in metastatic prostate cancer. The presentation questions whether overall survival should be the sole metric for evaluating interventions. Biographies: Sandy Srinivas, MD, Oncologist, Professor of Medicine (Oncology), Stanford University, Palo Alto, CA Relat...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Michael Morris presents a critical examination of optimal imaging standards for metastatic hormone-sensitive prostate cancer. The presentation explores PSMA imaging's potential while acknowledging its complications such as flare phenomenon and PSMA downregulation. Biographies: Michael Morris, MD, Prostate Cancer Section Head, GU On...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Bertrand Tombal examines treatment de-escalation strategies in metastatic hormone-naive prostate cancer. He explores three main approaches: stopping ADT while continuing ARPI, stopping ARPI while maintaining ADT, and revisiting intermittent androgen deprivation therapy, and emphasizes the importance of clinical trials like the P6 p...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Dana Rathkopf addresses the complex challenge of managing prostate cancer patients who show low-volume disease on conventional imaging but high-volume disease on next-generation PET imaging. The presentation explores evidence suggesting PET-only metastases may be more indolent than conventional imaging-visible disease. Biographies:...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Christopher Sweeney discusses strategies for managing early progression after combination therapy in prostate cancer. He emphasizes the importance of proper patient and tumor profiling while presenting ENZAMET trial data showing survival differences based on progression patterns. Biographies: Christopher Sweeney, MBBS, Professor of...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Maria De Santis presents an overview of managing frail patients with metastatic hormone-sensitive prostate cancer. The presentation explores treatment efficacy data and challenges in frail patients, while emphasizing the importance of supportive interventions and individualized treatment approaches. Biographies: Maria De Santis, MD...
|
- Details
- Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in oligometastatic castration-sensitive prostate cancer. The conversation explores validation studies demonstrating the test's prognostic value for overall survival and its potential to predict benefit from metastasis-directed therapy using data from the STOMP and ORIOLE trials. The...
|
